Roche Holding AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 174
- Registration Number
- NCT03032172
- Locations
- ๐บ๐ธ
Nemours Children's Hospital, Orlando, Florida, United States
๐บ๐ธBoston Childrens Hospital, Boston, Massachusetts, United States
๐บ๐ธColumbia University Medical Center, New York, New York, United States
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 778
- Registration Number
- NCT03024996
- Locations
- ๐บ๐ธ
University of Texas Southwestern Medical Center, Dallas, Texas, United States
๐จ๐ฆSunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
๐จ๐ฆPrincess Margaret Cancer Center, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT03020160
- Locations
- ๐ฆ๐บ
Royal Brisbane Hospital; Clinical Haematology, Brisbane, Queensland, Australia
๐ฏ๐ตNational Center for Child Health and Development, Tokyo, Japan
๐บ๐ธUniversity of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 759
- Registration Number
- NCT03016312
- Locations
- ๐บ๐ธ
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
๐บ๐ธCity of Hope Medical Grp Inc., Duarte, California, United States
๐บ๐ธUniversity of California San Diego, La Jolla, California, United States
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 109
- Registration Number
- NCT03001219
- Locations
- ๐จ๐ด
Servimed S.A.S., Bucaramanga, Colombia
๐ฒ๐ฝInvestigacion y Biomedicina de Chihuahua, Sociedad Civil, Chichuahua, Chihuahua, Mexico
๐ฒ๐ฝCentro Mรฉdico de las Amรฉricas, Merida, Yucatan, Mexico
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
- Conditions
- Bladder CancerPancreas CancerCholangiocellular Carcinoma
- Interventions
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT02999672
- Locations
- ๐ช๐ธ
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
๐ฎ๐นIRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy
๐ธ๐ฐNarodny onkologicky ustav, Bratislava, Slovakia
Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT02981290
- Locations
- ๐ณ๐ฟ
Christchurch Clinical Studies Trust, Christchurch, New Zealand
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT02975388
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
๐บ๐ธDaVita Clinical Research, Minneapolis, Minnesota, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT02972255
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
๐บ๐ธCovance Clinical Research Unit, Inc, Madison, Wisconsin, United States
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT02956850
- Locations
- ๐ณ๐ฑ
Academisch Medisch Centrum Universiteit Amsterdam; Dermatology and VU University Medical Center, Amsterdam, Netherlands
๐ง๐ฌGastroenterology department, Second clinic of internal diseases, Sofia, Bulgaria
๐ญ๐ฐQueen Mary Hospital, Hong Kong, Hong Kong